[Market Focus] Hanall Biopharma Surges Over 6% on Graves' Disease Drug Clinical Data Announcement

Hanall Biopharma is showing strong performance on September 4. The surge in buying is attributed to news that its partner company has announced positive clinical data for the autoimmune disease treatment "Batoclimab."

As of 9:46 a.m. on this day, Hanall Biopharma is trading at 33,950 won, up 2,450 won (7.78%) from the previous trading day.

Immunovant, Hanall Biopharma's partner, announced on September 3 (local time) data from a Phase 2 clinical trial of Batoclimab (HL161BKN) for Graves' disease, showing maintenance effects for six months after treatment completion. Graves' disease is an autoimmune disorder in which the immune system causes the thyroid gland to become overactive.

According to the clinical results, about 80% (17 patients) maintained normal thyroid hormone levels for six months after completing Batoclimab treatment. Of these, approximately 50% (8 patients) maintained stable hormone levels without any antithyroid medication, while 30% (5 patients) remained stable with only a small dose of antithyroid drugs.

This data represents the first case to suggest the potential of Batoclimab as a long-term, fundamental treatment for patients who did not respond to existing therapies.